This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Elsayed, Y. A. Articles by Sausville, E. A. Search for Related Content PubMed PubMed Citation Articles by Elsayed, Y. A. Articles by Sausville, E. A.

Selected Novel Anticancer Treatments Targeting Cell Signaling Proteins

Developmental Therapeutics Program Clinical Trials Unit, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Rockville, Maryland, USA

Correspondence: Edward A. Sausville, M.D., Ph.D., Developmental Therapeutic Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Executive Plaza North, Room 8018, 6130 Executive Boulevard, Rockville, Maryland 20852, USA. Telephone: 301-496-8720; Fax: 301-402-0831; e-mail: sausville{at}nih.gov

Empirical approaches to discovery of anticancer drugs and cancer treatment have made limited progress in the cure of cancer in the last several decades. Recent advances in technology and expanded knowledge of the molecular basis of tumorigenesis and metastasis have provided unique opportunities to design novel compounds that rationally target the abnormal molecular and biochemical signals leading to cancer. Several such novel agents have completed advanced stages in clinical development. The excellent clinical results achieved by some of these compounds are creating new paradigms in management of patients with neoplastic diseases. Clinical development of these agents also raises challenges to the traditional methods of drug evaluation and measurement of efficacy.

Key Words. Cell cycle • Cyclin-dependent kinase • Tyrosine kinase inhibitor • Chemotherapy • Histone deacetylase inhibitor • Proteasome inhibitor

This article has been cited by other articles:

				J. P. Jani, R. S. Finn, M. Campbell, K. G. Coleman, R. D. Connell, N. Currier, E. O. Emerson, E. Floyd, S. Harriman, J. C. Kath, et al. Discovery and Pharmacologic Characterization of CP-724,714, a Selective ErbB2 Tyrosine Kinase Inhibitor Cancer Res., October 15, 2007; 67(20): 9887 - 9893. [Abstract] [Full Text] [PDF]

				S. Roy, M. Kaur, C. Agarwal, M. Tecklenburg, R. A. Sclafani, and R. Agarwal p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells Mol. Cancer Ther., October 1, 2007; 6(10): 2696 - 2707. [Abstract] [Full Text] [PDF]

				C. J. Zheng, L. Y. Han, C. W. Yap, Z. L. Ji, Z. W. Cao, and Y. Z. Chen Therapeutic targets: progress of their exploration and investigation of their characteristics. Pharmacol. Rev., June 1, 2006; 58(2): 259 - 279. [Abstract] [Full Text] [PDF]

				C. Richard, D. Matthews, W. Duivenvoorden, J. Yau, P. S. Wright, and J. P.H. Th'ng Flavopiridol Sensitivity of Cancer Cells Isolated from Ascites and Pleural Fluids Clin. Cancer Res., May 1, 2005; 11(9): 3523 - 3529. [Abstract] [Full Text] [PDF]

				M. Michael and M.M. Doherty Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy J. Clin. Oncol., January 1, 2005; 23(1): 205 - 229. [Abstract] [Full Text] [PDF]

				M. L. Janmaat and G. Giaccone Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Oncologist, December 1, 2003; 8(6): 576 - 586. [Abstract] [Full Text] [PDF]

				E. K. Rowinsky Challenges of Developing Therapeutics That Target Signal Transduction in Patients With Gynecologic and Other Malignancies J. Clin. Oncol., May 15, 2003; 21(90100): 175s - 186. [Abstract] [Full Text] [PDF]

				R. Nahta, G. N. Hortobagyi, and F. J. Esteva Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention Oncologist, February 1, 2003; 8(1): 5 - 17. [Abstract] [Full Text] [PDF]

				D. B. Mendel, A. D. Laird, X. Xin, S. G. Louie, J. G. Christensen, G. Li, R. E. Schreck, T. J. Abrams, T. J. Ngai, L. B. Lee, et al. In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship Clin. Cancer Res., January 1, 2003; 9(1): 327 - 337. [Abstract] [Full Text] [PDF]

				F. Ciardiello and G. Tortora Inhibition of bcl-2 as cancer therapy Ann. Onc., April 1, 2002; 13(4): 501 - 502. [Full Text] [PDF]